NO20006065D0 - Cyanoiminokinoksalinderivater - Google Patents

Cyanoiminokinoksalinderivater

Info

Publication number
NO20006065D0
NO20006065D0 NO20006065A NO20006065A NO20006065D0 NO 20006065 D0 NO20006065 D0 NO 20006065D0 NO 20006065 A NO20006065 A NO 20006065A NO 20006065 A NO20006065 A NO 20006065A NO 20006065 D0 NO20006065 D0 NO 20006065D0
Authority
NO
Norway
Prior art keywords
ncn
independently
hydrogen
cyanoiminokinoksalinderivater
cyanoiminoquinoxaline
Prior art date
Application number
NO20006065A
Other languages
Norwegian (no)
Other versions
NO20006065L (en
Inventor
Susumu Takada
Nobuo Chomei
Tsuyoshi Kihara
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20006065D0 publication Critical patent/NO20006065D0/en
Publication of NO20006065L publication Critical patent/NO20006065L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A cyanoiminoquinoxaline derivative of the formula (II) is useful as a preventive or therapeutic agent for diseases due to hyperexcitation of glutamate receptors. <CHEM> (wherein, X and Y each is independently O or NCN, provided that at least one of X and Y is NCN; R<1>, R<2>, R<3>, and R<4> each is independently hydrogen, halogen, nitro, optionally substituted heterocyclic group etc.; R<5> is hydrogen etc.; R<1> and R<2>, R<2> and R<3>, R<3> and R<4>, and R<4> and R<5>, each taken together with the adjacent atoms may form a carbocycle which may be substituted or may contain a heteroatom(s).)
NO20006065A 1998-06-01 2000-11-29 Cyanoiminokinoksalinderivater NO20006065L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15101798 1998-06-01
PCT/JP1999/002822 WO1999062887A1 (en) 1998-06-01 1999-05-28 Cyanoiminoquinoxaline derivatives

Publications (2)

Publication Number Publication Date
NO20006065D0 true NO20006065D0 (en) 2000-11-29
NO20006065L NO20006065L (en) 2001-01-31

Family

ID=15509486

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006065A NO20006065L (en) 1998-06-01 2000-11-29 Cyanoiminokinoksalinderivater

Country Status (20)

Country Link
US (1) US6525054B1 (en)
EP (1) EP1097927B1 (en)
JP (1) JP3231338B2 (en)
KR (1) KR20010043981A (en)
CN (1) CN1304404A (en)
AT (1) ATE333447T1 (en)
AU (1) AU744274B2 (en)
BR (1) BR9910859A (en)
CA (1) CA2333515A1 (en)
DE (1) DE69932441T2 (en)
HU (1) HUP0102854A3 (en)
ID (1) ID26809A (en)
IL (1) IL139783A0 (en)
NO (1) NO20006065L (en)
NZ (1) NZ508280A (en)
PL (1) PL344406A1 (en)
RU (1) RU2217426C2 (en)
TR (1) TR200003572T2 (en)
WO (1) WO1999062887A1 (en)
ZA (1) ZA200006838B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100581344B1 (en) * 2003-05-02 2006-05-23 주식회사디엔에이링크 Composition for inhibiting telomerase activity
EP2241557A1 (en) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses
CN104177595A (en) * 2013-05-28 2014-12-03 海洋王照明科技股份有限公司 Quinoxalinyl-containing polymer and preparation method thereof and organic solar energy cell device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
AU688459B2 (en) 1994-04-08 1998-03-12 Shionogi & Co., Ltd. Oxopyridinylquinoxaline derivative
WO1996010023A1 (en) 1994-09-27 1996-04-04 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxalindione derivative
HUT76302A (en) * 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor

Also Published As

Publication number Publication date
EP1097927A1 (en) 2001-05-09
CN1304404A (en) 2001-07-18
RU2217426C2 (en) 2003-11-27
EP1097927A4 (en) 2002-08-07
JP3231338B2 (en) 2001-11-19
HUP0102854A3 (en) 2002-07-29
EP1097927B1 (en) 2006-07-19
NZ508280A (en) 2002-09-27
CA2333515A1 (en) 1999-12-09
AU744274B2 (en) 2002-02-21
DE69932441D1 (en) 2006-08-31
ID26809A (en) 2001-02-08
ATE333447T1 (en) 2006-08-15
ZA200006838B (en) 2001-05-23
NO20006065L (en) 2001-01-31
WO1999062887A1 (en) 1999-12-09
PL344406A1 (en) 2001-11-05
US6525054B1 (en) 2003-02-25
DE69932441T2 (en) 2007-03-15
HUP0102854A2 (en) 2002-03-28
KR20010043981A (en) 2001-05-25
BR9910859A (en) 2001-03-13
TR200003572T2 (en) 2001-06-21
IL139783A0 (en) 2002-02-10
AU3955399A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
ATE180468T1 (en) ANTHRANILIC ACID DERIVATIVES
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
PT870768E (en) AZAINDOLE-ETHYLAMINE DERIVATIVES AS NICOTYCHETIC LIGACATION AGENTS TO ACETYLCOLINE RECEPTORS
GB9801690D0 (en) Therapeutic agents
ATE197710T1 (en) QUINAZOLINE DERIVATIVES
BR9910621A (en) New 2-alkyl imidazole substituted compounds
ATE177096T1 (en) 4-SUBSTITUTED 1,2,4-TRIAZOLE DERIVATIVES
EE200000059A (en) Tetrahydro-gamma-carbolines
DE69808099D1 (en) SUBSTITUTED 6-ALKYLPHENANTHRIDINE
AR003137A1 (en) A PHARMACEUTICAL COMPOSITION TO TREAT LEUKEMIA
ATE246686T1 (en) PYRROLOCARBAZOLE DERIVATIVES
NO20006065D0 (en) Cyanoiminokinoksalinderivater
UY26568A1 (en) NEW DERIVATIVES OF HETEROCYCLIC AMIDES
ATE222583T1 (en) DERIVATIVES OF SUBSTITUTED AMIDINONAPHTHYL ESTER
FI822706L (en) FRAMEWORK FOR THE PHARMACOLOGICAL ACTIVATION OF ACTIVE HETEROARYLOXIPROPANOLAMINER
ES2168119T3 (en) DERIVATIVES OF QUINOXALINE FOR THE TREATMENT OF TINNITUS.
AR003129A1 (en) BENCIMIDAZOLE 2-SUBSTITUTED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application